In ₹ Crore except Per Share Latest Annual	EMCURE FY26	MANKIND FY26	ALKEM FY26	TORNTPHARM FY26	Peer Average
Valuation — at last close
P/E	36.41×	47.64×	◆ 25.61×	70.40×	47.88× -24%
P/B	6.80×	5.59×	◆ 4.27×	18.16×	9.34× -27%
EV/EBITDA	◆ 18.64×	26.45×	19.51×	38.23×	28.06× -34%
Market Cap	₹33,669 Cr	₹91,142 Cr	₹58,944 Cr	₹1.52L Cr	₹1.01L Cr -67%
Growth
Revenue CAGR 3Y	—	◆ 17.73%	8.25%	13.27%	13.08%
Revenue CAGR 5Y	—	—	10.09%	◆ 11.80%	10.95%
Net Income CAGR 3Y	—	13.96%	◆ 32.67%	19.75%	22.13%
Revenue YoY (latest Q)	22.85%	17.33%	10.95%	◆ 50.79%	26.36% -13%
Net Income YoY (latest Q)	36.17%	◆ 37.67%	-22.00%	-9.64%	2.01% +1700%
Profitability
EBITDA Margin	20.26%	25.34%	20.43%	◆ 32.61%	26.13% -22%
Net Income Margin	10.23%	13.57%	◆ 15.98%	15.29%	14.95% -32%
Return on Common Equity	19.68%	12.49%	17.84%	◆ 27.07%	19.13% +3%
Return on Capital Employed	◆ 25.74%	12.51%	17.59%	14.88%	14.99% +72%
Return on Assets	10.55%	6.94%	◆ 12.19%	7.21%	8.78% +20%
Credit & Quality
Total Debt/Equity	0.24×	0.38×	◆ 0.11×	0.84×	0.44× -46%
Interest Coverage	10.09×	4.27×	◆ 16.32×	8.94×	9.84× +3%
Scale — latest FY
Revenue / Total Income	₹9,204 Cr	₹14,278 Cr	₹14,712 Cr	₹13,980 Cr	₹14,323 Cr -36%
Net Income	₹941 Cr	₹1,938 Cr	₹2,351 Cr	₹2,138 Cr	₹2,142 Cr -56%
Total Assets	₹9,612 Cr	₹28,080 Cr	₹20,873 Cr	₹44,312 Cr	₹31,088 Cr -69%
EPS	₹48.77	₹46.35	₹192.51	₹63.92	₹100.93 -52%
Book Value per Share	₹261.09	₹394.87	₹1,156.01	₹247.86	₹599.58 -56%

◆ best value in the comp set per metric · Δ = subject vs average of the other companies.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.